SARM1

NAD(+) hydrolase SARM1 · Q6SZW1 · SARM1 on Sugi Atlas →

7,518 patent compounds predicted against SARM1, 5,336 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL106666	0.63	3/20
SCHEMBL1269347	0.61	3/20
SCHEMBL1457476	0.61	3/20
SCHEMBL1457477	0.61	3/20
Lansoprazole (SCHEMBL22365)	0.61	3/20
Lansoprazole (SCHEMBL22366)	0.61	3/20
Dexlansoprazole (SCHEMBL44975)	0.61	3/20
Lansoprazole (SCHEMBL1559598)	0.61	3/20
Lansoprazole (SCHEMBL1067267)	0.60	3/20
Dexlansoprazole (SCHEMBL1067269)	0.60	3/20
Dexlansoprazole (SCHEMBL1067274)	0.60	3/20
Lansoprazole (SCHEMBL1269346)	0.60	3/20
Lansoprazole (SCHEMBL1274164)	0.60	3/20
Dexlansoprazole (SCHEMBL1457415)	0.60	3/20
Lansoprazole (SCHEMBL1457400)	0.59	3/20
Dexlansoprazole (SCHEMBL1457401)	0.59	3/20
Lansoprazole (SCHEMBL1457172)	0.57	3/20
Dexlansoprazole (SCHEMBL1457174)	0.57	3/20
Lansoprazole (SCHEMBL1559423)	0.57	3/20
Lansoprazole (SCHEMBL1457598)	0.56	3/20

Clinical trials — most relevant to SARM1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Efficacy and Safety of Oral Nicotinamide as an Adjunctive Therapy in Patients With Sepsis	PHASE4	NOT_YET_RECRUITING
cindilizumab + Bevacizumab + Coenzyme I for Injection in Unresectable Hepatocellular Carcinoma	PHASE4	UNKNOWN
Evaluation of Nicotinamide Riboside in Prevention of Small Fiber Axon Degeneration and Promotion of Nerve Regeneration	PHASE2	COMPLETED
Effects of Vitamin B3 in Patients With Ataxia Telangiectasia	PHASE2	COMPLETED
Sirtuin-NAD Activator in Alzheimer's Disease	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Effects of Nicotinamide Riboside on the Clinical Outcome of Covid-19 in the Elderly	PHASE2	WITHDRAWN
A Study of APO866 for the Treatment of Cutaneous T-cell Lymphoma	PHASE2	COMPLETED
Metabolic Cofactor Supplementation in Alzheimer's Disease (AD) and Parkinson's Disease (PD) Patients	PHASE2	COMPLETED
Nicotinamide Riboside on Mitochondrial Function in Li-Fraumeni Syndrome	PHASE1/PHASE2	COMPLETED
31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Amyotrophic Lateral Sclerosis (REPAIR-ALS)	PHASE2	WITHDRAWN
Metabolic Cofactor Supplementation in Obese Patients With Non-Alcoholic Fatty Liver Disease	PHASE2	COMPLETED
Nicotinamide Adenine Dinucleotide and Skeletal Muscle Metabolic Phenotype	PHASE2	UNKNOWN
31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Parkinson's Disease	PHASE2	COMPLETED
Phase 1a Single Ascending Dose Study of MIB-725 in Healthy Adults	PHASE1	RECRUITING
Tracing the Metabolic Flux of Orally Administered NAD+ Precursors	PHASE1	RECRUITING
Effects of Nicotinamide Riboside on Bioenergetics and Oxidative Stress in Mild Cognitive Impairment/Alzheimer's Dementia	EARLY_PHASE1	ACTIVE_NOT_RECRUITING
Sirtuin1 in COVID19 Patients	nan	UNKNOWN
Investigate eNAMPT in Multiple Myeloma Biology and Establish Its Role in Disease Progression	nan	COMPLETED
Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With Nicotinamide Riboside	nan	UNKNOWN
Project SIRT6 Activator	nan	RECRUITING
Multi-omics Study in Citrin Deficiency	nan	ACTIVE_NOT_RECRUITING
Impact of Nicotinamide Riboside (NR) on Kidney Function in Patients Undergoing Cardiac Surgery	nan	NOT_YET_RECRUITING
Nicotinamide Riboside Clinical Trial for GWI	nan	RECRUITING
Influence of WNT4 VEZT FSHB and SIRT1 SNPs in Endometriosis: a Case Control Study of the Sardinian Population	nan	UNKNOWN
Inflammation in COPD and the Effect of Nicotinamide Riboside	nan	COMPLETED
NR Supplementation and Exercise	nan	COMPLETED
Mitochondrial Health and Hemodynamic Instability Related to Renal Replacement Therapy in Critically Ill Patients	nan	UNKNOWN
Effects of Protein Hydrolysate Supplement on Systemic Muscle Function Markers Following Resistance Type Exercise in Male Subjects	nan	COMPLETED
The Safety and Efficacy Study of RiaGev in Healthy Adults	nan	UNKNOWN
Investigate the Efficacy of Using NMN to Improve Embryo Development Capacity.	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a SARM1 binder may also engage these)

Protein	Name	Similarity
Q6PDS3	—	0.999	Q6PDS3 →
D3ZUM2	—	0.998	D3ZUM2 →
I3L5V6	—	0.995	I3L5V6 →
Q9ESJ4	—	0.976	Q9ESJ4 →
INF2	Inverted formin-2	0.975	landscape →
Q3URY6	—	0.975	Q3URY6 →
PINK1	Serine/threonine-protein kinase PINK1, mitochondrial	0.974	landscape →
Q9NZQ3	—	0.974	Q9NZQ3 →
F1QWA8	—	0.974	F1QWA8 →
TELO2	Telomere length regulation protein TEL2 homolog	0.973	landscape →
RNF31	E3 ubiquitin-protein ligase RNF31	0.973	landscape →
P47823	—	0.973	P47823 →
Q86Y56	—	0.973	Q86Y56 →
Q9BSK4	—	0.972	Q9BSK4 →
Q99MQ3	—	0.972	Q99MQ3 →
MAP3K6	Mitogen-activated protein kinase kinase kinase 6	0.972	landscape →
O43304	—	0.972	O43304 →
Q924T7	—	0.972	Q924T7 →
Q96NW4	—	0.972	Q96NW4 →
Q9BXL6	—	0.972	Q9BXL6 →
GRB7	Growth factor receptor-bound protein 7	0.971	landscape →
Q99LG4	—	0.971	Q99LG4 →
Q8NE28	—	0.971	Q8NE28 →
Q5REW9	—	0.971	Q5REW9 →
B2RUP2	—	0.971	B2RUP2 →
Q9Y613	—	0.971	Q9Y613 →
EIF2B5	Translation initiation factor eIF2B subunit epsilon	0.971	landscape →
A7MB11	—	0.971	A7MB11 →
B5DFA1	—	0.971	B5DFA1 →
P0CI65	—	0.970	P0CI65 →